Bayer マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Bill Anderson

最高経営責任者

€9.2m

報酬総額

CEO給与比率	24.36%
CEO在任期間	2.9yrs
CEOの所有権	n/a
経営陣の平均在職期間	3yrs
取締役会の平均在任期間	7.1yrs

経営陣の近況

Recent updates

CEO報酬分析

Bayer の収益と比較して、Bill Anderson の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2025	€9m	€2m	-€4b
Sep 30 2025	n/a	n/a	-€198m
Jun 30 2025	n/a	n/a	-€3b
Mar 31 2025	n/a	n/a	-€3b
Dec 31 2024	€9m	€2m	-€3b
Sep 30 2024	n/a	n/a	-€880m
Jun 30 2024	n/a	n/a	-€1b
Mar 31 2024	n/a	n/a	-€3b
Dec 31 2023	€12m	€2m	-€3b

報酬と市場: Billの総報酬 ($USD 10.64M ) は、 US市場 ($USD 13.50M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Billの報酬は増加しましたが、会社は利益を上げていません。

CEO

Bill Anderson (59 yo)

2.9yrs

在職期間

€9,236,000

報酬

Mr. William N. Anderson, also known as Bill, is Member of Management Board of Bayer Aktiengesellschaft from April 1, 2023 and also serves as its Chairman of the Management Board and Chief Executive Officer...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
William Anderson	Chairman of the Management Board & CEO	2.9yrs	€9.24m	データなし
Wolfgang Nickl	CFO & Member of Management Board	7.9yrs	€3.82m	データなし
Stefan Oelrich	Head of the Pharmaceuticals Division & Member of the Board of Management	7.3yrs	€3.79m	データなし
Heike Prinz	Chief Talent Officer	2.5yrs	€3.97m	データなし
Rodrigo Santos	Member of Management Board & President of the Crop Science Division	4.2yrs	€3.77m	データなし
Julio Triana	Member of Management Board & President of Consumer Health Division	1.9yrs	€3.58m	データなし
Judith Hartmann	Member of Management Board	no data	データなし	データなし
Jost Reinhard	Senior VP & Head of Investor Relations	2.4yrs	データなし	データなし
Bill Dodero	General Counsel and Senior VP of Law Patents & Compliance	3.2yrs	データなし	データなし
Michael Preuss	Head of Communications	9.8yrs	データなし	データなし
Bernd-Peter Bier	Head of Group Finance	no data	データなし	データなし

3.0yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: BAYZ.Fの経営陣は経験豊富であると考えられます ( 3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Paul M. Achleitner	Member of Supervisory Board	23.9yrs	€233.00k	データなし
Ertharin Cousin	Independent Member of the Supervisory Board	6.4yrs	€240.00k	データなし
Alberto Weisser	Independent Supervisory Board Member	4.9yrs	€223.00k	データなし
Colleen Goggins	Independent Member of Supervisory Board	8.9yrs	€233.00k	データなし
Lori Schechter	Independent Supervisory Board Member	1.9yrs	€304.00k	データなし
Horst Baier	Independent Member of Supervisory Board	5.9yrs	€336.00k	データなし
Heike Hausfeld	Vice Chairwoman of Supervisory Board	8.9yrs	€350.00k	データなし
André van Broich	Member of Supervisory Board	13.9yrs	€279.00k	データなし
Frank Löllgen	Member of Supervisory Board	10.3yrs	€268.00k	データなし
Norbert Winkeljohann	Independent Chairman of Supervisory Board	7.8yrs	€518.00k	データなし
Andrea Sacher	Member of Supervisory Board	5.5yrs	€244.00k	データなし
Michael Westmeier	Employee Representative Member of the Supervisory Board	3.9yrs	€241.00k	データなし

7.1yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: BAYZ.Fの取締役会は経験豊富であると考えられます ( 7.1年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/03/12 16:17
終値	2026/03/12 00:00
収益	2025/12/31
年間収益	2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成する分析モデルの詳細は当社の Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや YouTubeのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Bayer Aktiengesellschaft 19 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。39

アナリスト	機関
Rafael Bonardell Trianes	Banco de Sabadell. S.A.
Emily Field	Barclays
Charles Pitman	Barclays

Bayer マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Bayer Aktiengesellschaft, Annual General Meeting, Apr 24, 2026

Bayer AG Announces Chief Financial Officer Changes

Bayer Announces Executive Changes for North America

Bayer Announces Changes to CFO for Crop Science Division, Effective July 1, 2025

Bayer Announces Management Changes, Effective April 15, 2025

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Recent updates

Bayer Aktiengesellschaft to Report Q4, 2026 Results on Feb 24, 2027

Bayer Aktiengesellschaft to Report Q3, 2026 Results on Nov 03, 2026

Missouri Court Grants Preliminary Approval of Roundup Class Settlement to Resolve Current and Future Claims

Bayer Aktiengesellschaft, Annual General Meeting, Apr 24, 2026

Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

Bayer Announces XOFIGO (Radium-223 Dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit In PEACE-3 Trial In Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases

Monsanto Announces Roundup™ Class Settlement Agreement to Resolve Current and Future Claims

Bayer's Asundexian Demonstrated A Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo

Bayer to Present Results from Phase III Oceanic-Stroke Study of Asundexian in Secondary Stroke Prevention

Askbio Inc. Announces Fda Acceptance of Investigational New Drug (Ind) Application for Ab-1009 Gene Therapy for Treatment of Late-Onset Pompe Disease

Bayer Starts Phase IIa Study for Treatment of Patients with Alport Syndrome

Bayer Starts New Phase III Study with Mirena®? for the Treatment of Nonatypical Endometrial Hyperplasia

Bayer Announces Positive Topline Results from the Global Phase III Study Oceanic-Stroke, with Its Investigational, Once Daily, Oral FXIa Inhibitor asundexian

U.S. FDA Approves HYRNUO®? (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Bayer Aktiengesellschaft to Report Q2, 2026 Results on Aug 04, 2026

Bayer AG Announces Chief Financial Officer Changes

Bayer Announces New Phase III Investigational Data from the Pivotal Fine-One Trial

Bayer Announces U.S. Food and Drug Administration Approval for Moderate to Severe Hot Flashes Due to Menopause

Hesperos and Bayer Consumer Health Develop First Human-On-A-Chip Model of Stress-Induced Cognitive Dysfunction

Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson's Disease

Bayer®? Aspirin Introduces Aspirina to the U.S. Pain Market

Bayer Aktiengesellschaft to Report Q1, 2026 Results on May 12, 2026

Bayer Aktiengesellschaft to Report Q3, 2025 Results on Nov 12, 2025

Bayer Ag and BlueRock Therapeutics LP Announces First Patient Receives Investigational Therapy in Phase 1/2a Clinical Trial of OpCT-001 for the Treatment of Primary Photoreceptor Diseases

Bayer Announces Executive Changes for North America

Bayer Files for Approval of Gadoquatrane to the US Food and Drug Administration

U.S. FDA Approves Third Indication of Darolutamide for Patients with Advanced Prostate Cancer

Vividion Therapeutics, Inc. and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor

Elinzanetant Significantly Reduces Frequency of Moderate to Severe Vasomotor Symptoms Associated with Endocrine Therapy for Breast Cancer in Phase III Oasis-4 Study as Per Bayer

Bayer's XOFIGO (Radium-223 Dectloride) Combination Data Showcases Clinical Benefits in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases

Bayer Highlights New Data from Oncology and Women’S Health Portfolios At 2025 Asco Annual Meeting

Bayer Initiates Phase I Study Targeting GPC3 with Actinium-225 Radiopharmaceutical in Patients with Advanced Hepatocellular Carcinoma

Bayer Announces Changes to CFO for Crop Science Division, Effective July 1, 2025

Bayer to Unveil Latest NUBEQA®? (Darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual Meeting

Bayer Receives Full FDA Approval For VITRAKVI®? As First-In-Class TRK Inhibitor

Elliott Reportedly Gauge Investor Interest in Bayer's Consumer Health Business

Bayer Announces Management Changes, Effective April 15, 2025

Bayer Announces U.S. FDA Accepts Supplemental New Drug Application Under Priority Review for New Indication for KERENDIA®? (Finerenone) in Patients with Heart Failure with Left Ventricular Ejection Fraction of 40%

Bayer Introduces Vyconic Soybeans at Commodity Classic 2025

Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking New Indication for KERENDIA® (finerenone)

Bayer Announces Positive Topline Results of Phase Iii Study Oasis 4 Investigating Elinzanetant

Bayer Submits Application in China for Third Indication of Darolutamide

Bayer Aktiengesellschaft to Report Q2, 2025 Results on Aug 06, 2025

Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF =40% at AHA 2024

Bayer and Liveo Research Launches Blister Packaging with Improved Environmental Footprint

Bayer Submits Application for Third Indication of Darolutamide in the EU

U.S. Food and Drug Administration Accepts New Drug Application for Bayer's Elinzanetant

Bayer Ag and BlueRock Therapeutics LP Announces Positive 24-Month Data from exPDite

Bayer Submits Application to U.S. FDA for Third Indication of darolutamide

Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer Announces Late-Breaking KERENDIA® (finerenone) Investigational Data Presented

Bayer to Present Phase III Kerendia (Finerenone) Data

Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Bayer Submits New Drug Application to U.S. FDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause

Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual Meeting

Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate Cancer

Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's Elinzanetant

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Bayer Announces Start of Phase II Clinical Trial with BAY3018250

Bayer Aktiengesellschaft to Report Q1, 2024 Results on May 14, 2024

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer Starts Phase II Study Nirvana to Evaluate Elinzanetant in Women with Sleep Disruptments Associated with Menopause

Williams Hart & Boundas Wins Against Bayer

Bayer Announces OCEANIC-AF Study Starts Early Due to Lack of Efficacy

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

マネジメント基準チェック /34